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Although abundant in well-differentiated rat thyroid cells, Rap1GAP expression was extinguished in a subset
of human thyroid tumor-derived cell lines. Intriguingly, Rap1GAP was downregulated selectively in tumor cell
lines that had acquired a mesenchymal morphology. Restoring Rap1GAP expression to these cells inhibited
cell migration and invasion, effects that were correlated with the inhibition of Rap1 and Rac1 activity. The
reexpression of Rap1GAP also inhibited DNA synthesis and anchorage-independent proliferation. Conversely,
eliminating Rap1GAP expression in rat thyroid cells induced a transient increase in cell number. Strikingly,
Rap1GAP expression was abolished by Ras transformation. The downregulation of Rap1GAP by Ras required
the activation of the Raf/MEK/extracellular signal-regulated kinase cascade and was correlated with the
induction of mesenchymal morphology and migratory behavior. Remarkably, the acute expression of oncogenic
Ras was sufficient to downregulate Rap1GAP expression in rat thyroid cells, identifying Rap1GAP as a novel
target of oncogenic Ras. Collectively, these data implicate Rap1GAP as a putative tumor/invasion suppressor
in the thyroid. In support of that notion, Rap1GAP was highly expressed in normal human thyroid cells and
downregulated in primary thyroid tumors.
Rap1GAP (30, 33) is a member of a family of GTPase-
activating proteins (GAPs) for Rap1/2 GTPases that includes
the splice variant Rap1GAPII, SPA-1, and E6TP1. Rap1GAP
shares structural similarities with the RhebGAP tuberin. Tu-
berin is subject to mutational inactivation and loss in tuberous
sclerosis, a disease syndrome associated with the formation of
multiple benign tumors (15, 19, 22, 37). The downregulation of
E6TP1 by human papillomavirus E6 protein is believed to
contribute to cervical cancer (10, 11), and an SPA-1 deficiency
in mice results in a spectrum of myelodysplastic disorders sim-
ilar to chronic myelogenous leukemia (13). The rap1GAP gene
has been mapped to 1p35-36, a chromosomal region subject to
deletion in a variety of human tumors including breast (28) and
endocrine (41) neoplasia. Recently, decreased expression and
loss of heterozygosity for Rap1GAP were reported for human
oropharyngeal squamous cell (43) and pancreatic (21, 42) car-
cinomas.
Rap1GAP is abundant in rat thyroid epithelial cells, where
thyroid-stimulating hormone (TSH) regulates Rap1GAP protein
stability. The stable overexpression of Rap1GAP in thyroid cells
impaired DNA synthesis and the growth rate, and based on this,
we suggested that Rap1GAP might function as a tumor suppres-
sor (34). We now provide further support for this idea. Eliminat-
ing Rap1GAP expression in differentiated rat thyroid cells in-
duced a transient increase in cell proliferation. Moreover, while
highly expressed in normal thyroid follicular cells, Rap1GAP ex-
pression was downregulated in primary thyroid tumors and in
thyroid carcinoma cell lines. In vitro, decreased expression of
Rap1GAP was observed selectively in thyroid carcinoma cell
lines that exhibited migratory and invasive properties. Restor-
ing Rap1GAP expression in these cells inhibited not only cell
proliferation but also tumor cell migration and invasion. Re-
markably, acute or chronic expression of activated Ras in rat
thyroid cells abolished Rap1GAP expression. These findings
identify Rap1GAP as being a putative tumor/invasion suppres-
sor in thyroid cells and a novel target of oncogenic Ras.
MATERIALS AND METHODS
Reagents. Rap1GAP antibodies generously provided by Michiyuki Matsuda
(Osaka University) and purchased from Santa Cruz (Santa Cruz, CA) were used.
Hemagglutinin (HA) antibody was a kind gift from Jeffrey Field (University of
Pennsylvania). Rap1, extracellular signal-regulated kinase 2 (ERK2), and actin
antibodies were purchased from Santa Cruz (Santa Cruz, CA). Vimentin anti-
body was purchased from Sigma (Saint Louis, MO), E-cadherin antibody was
purchased from R&D Systems (Minneapolis, MN), Rac1 antibody was pur-
chased from Upstate (Lake Placid, NY), and phospho-ERK and AKT antibodies
were purchased from Cell Signaling (Beverly, MA). The 2-chimerin antibody
was described previously (38).
Cell culture. Wistar rat thyroid (WRT) cells were propagated in Coon’s mod-
ified Ham’s F-12 medium containing TSH, insulin, transferrin, and 5% calf
serum (referred to as 3H medium). Cells were starved in growth factor- and
serum-free Coon’s modified Ham’s F-12 or basal medium. NPA and KAT10
papillary thyroid carcinoma lines, FTC133 and WRO follicular thyroid carci-
noma lines, and ARO, KAT4B, and SW1736 anaplastic thyroid carcinoma lines
were studied. FTC-133 cells (12) were obtained from O. Clark (University of
California, San Francisco). KAT10 and KAT4B cells were a generous gift from
K. Ain (University of Kentucky), and SW1736 cells were obtained from M. S.
Brose’s laboratory. ARO, NPA, and WRO cells (29) were kindly provided by M.
Ringel (The Ohio State University College of Medicine). FTC-133 cells were
grown in 3H medium and starved in basal medium. ARO, NPA, and WRO cells
were propagated in RPMI–10% fetal bovine serum. KAT10, KAT4B, and
SW1736 cells were grown in phenol red-free RPMI supplemented with 10% fetal
bovine serum, nonessential amino acids, and sodium pyruvate. Starvation was
performed in serum-free RPMI medium. RasV12-transformed WRT cells (7, 26)
were propagated in 3H medium and starved in basal medium.
Transient transfection and anchorage-independent proliferation. Transfec-
tion was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer’s recommendations. Cells were plated in six-well
* Corresponding author. Mailing address: Department of Pharma-
cology, University of Pennsylvania School of Medicine, 421 Curie
Blvd., 1251 BRB II/III, Philadelphia, PA 19104-6061. Phone: (215)
898-1909. Fax: (215) 573-2236. E-mail: meinkoth@pharm.med.upenn
.edu.
 Published ahead of print on 23 July 2007.
6647
plates 18 h prior to transfection, transferred into Opti-MEM I (Invitrogen), and
exposed to 4 g of pShuttle or pShuttle-HA-Rap1GAP DNA and 8 l of
Lipofectamine 2000. Twenty-four hours posttransfection, cells (103) were resus-
pended in 1.5 ml 0.33% agar in 3H medium and plated onto a bottom layer of
0.5% agar. Cells were refed every 4 to 5 days for 3 to 4 weeks. Colonies were
visualized by staining with 2 mg/ml MTT (methylthiazolyldiphenyl-tetrazolium
bromide) for 16 h at 37°C.
DNA synthesis. FTC-133 cells plated onto glass coverslips were transfected
with 8 g of pShuttle or pShuttle-HA-Rap1GAP DNA and 10 l of Lipo-
fectamine 2000 in 1 ml of Opti-MEM I. After 5 h, cells were transferred into 3H
medium. After 24 and 48 h, cells were pulse-labeled with bromodeoxyuridine
(BrdU) for 4 h, fixed, and stained for HA-Rap1GAP and BrdU as previously
described (34).
Viral infection. Cells were infected overnight in basal or serum-free medium
and transferred into growth medium for 24 h before they were used in experi-
ments. HA-Rap1GAP and HA-Rap1bN17 adenoviruses were constructed using
the AdEasy vector system (Q-Biogene, Carlsbad, CA). HA-pShuttle was kindly
provided by M. Kazanietz (University of Pennsylvania). Rap1GAP cDNA was
obtained by PCR from pCMV2-FLAG-Rap1GAP, kindly provided by Lawrence
Quilliam (Indiana University). Rap1b cDNA was obtained by reverse transcrip-
tion (RT)-PCR from WRT cell RNA. The PCR fragments were cloned into
EcoRV and XhoI sites of HA-pShuttle. Site-directed mutagenesis of Rap1b to
Rap1bN17 was performed as described previously (34). The resulting constructs
were used for recombination with adenoviral DNA in BJ5183 competent cells.
QBI-293A cells were transfected with recombinants and analyzed for adenovirus
production by plaque assay. Adenoviruses were propagated according to the
manufacturer’s recommendations, and titers were determined by using the Ad-
eno-X rapid titer kit (Clontech, Mountain View, CA). Control virus (LacZ) was
used at an equal multiplicity of infection (MOI) (infectious units/cell for banded
viruses and particles/cell for unbanded viruses) as test viruses.
HA-RasV12 adenovirus was constructed as described previously (8). Adeno-
viruses expressing Ras effector domain mutants were generated in a similar
fashion. A virus expressing activated MEK1 was a kind gift from Zohre German
(UT Southwestern). WRT cells were infected with viruses overnight in basal
medium, washed, and transferred into fresh 3H medium for the indicated times.
2-Chimerin adenovirus was described elsewhere previously (6).
Wound assay. Confluent monolayers of control and infected cells (at 24 to 48 h
postinfection) were wounded with a pipette tip, refed to remove floating cells,
and imaged immediately and at various times thereafter using a Nikon Eclipse
TE2000 microscope.
Transwell migration assay. Cells were trypsinized and counted, and 105 cells
(in 100 l) were plated into the upper chamber of Transwell 24-well plates
(Fisher, Pittsburgh, PA) containing 8-m-pore-size filters. FTC-133 and
RasV12S35 cells were plated in 3H medium, and the lower chamber was sup-
plemented with the same medium. NPA cells were plated in serum-free RPMI
medium and exposed to RPMI–10% fetal calf serum in the lower chamber.
Migration was analyzed after 24 h. Triplicate samples were analyzed for total and
migrated cells. For migrated cells, cells on the top of the filters were removed
using a cotton swab. Cells were fixed in 3.7% formaldehyde–phosphate-buffered
saline (PBS) for 15 min, stained with 0.1% crystal violet for 15 min, and solubi-
lized in 1% sodium deoxycholate, and the absorbance was read at 450 nm. The
percent migrated cells was calculated against total cells, which was set as 100%.
To assess invasion, FTC-133 and RasV12S35 cells were plated in basal medium
containing 1% fetal calf serum in the upper chamber of BioCoat Matrigel
Invasion chambers (BD Biosciences, Bedford, MA) and exposed to epidermal
growth factor (10 ng/ml)-supplemented 3H medium in the lower chamber. Per-
cent invasion was analyzed in triplicate samples after 72 h.
RT-PCR. RNA was isolated using TRIzol (Invitrogen). RT-PCR was per-
formed using the AccessQuick RT-PCR system (Promega, Madison, WI) ac-
cording to the manufacturer’s protocol. Briefly, 3 g RNA was mixed with 24 l
master mix containing Rap1GAP or -actin primers, heated at 45°C for 1 h, and
followed with PCR cycling as specified by manufacturer. Reaction products were
analyzed on 1.5% agarose gels and imaged using GelDoc XR and Quantity One
4.5.2 software (Bio-Rad, Hercules, CA).
Rap1 and Rac1 activity. Rap1 activation was analyzed as described previously
(35), and Rac1 activation was analyzed as described previously (38). Rac1 activity
was assessed in growing RasV12S35 cells and 4 h after replating FTC-133 cells.
Cells were lysed in 600 l Rac lysis buffer (20 mM Tris-HCl [pH 8.0], 100 mM
NaCl, 10 mM MgCl2, 1% Triton X-100, 50 g glutathione S-transferase–Pak–
CRIB). Precleared lysate (450 l) was incubated with 50 l glutathione-Sepha-
rose 4B, with rotating for 1 h at 4°C. Beads were washed three times with lysis
buffer, resuspended in 2 sample buffer, boiled, and analyzed on 12% gels. Total
cell extracts (30 l) were run in parallel as a loading control.
Adhesion assay. FTC-133 cells were trypsinized, counted, and plated on lami-
nin-treated coverslips. After various times, cells were fixed, stained for HA-
Rap1GAP and actin using rhodamine-conjugated phalloidin, and analyzed using
a Zeiss axiophot fluorescence microscope.
siRNA transfection and cell proliferation assays. Small interfering RNA
(siRNA) duplexes (100 nM) were introduced into WRT cells (1.3  106 to 1.5 
106 cells) using the Amaxa Nucleofector (Germany). Scrambled siRNA (catalog
no. 1027280) and Rap1GAP siRNA duplexes 1 (catalog no. SI01737043) and 2
(catalog no. SI01737050) were purchased from QIAGEN (Valencia, CA).
siRNA-transfected cells were plated in 96-well plates (105 cells/well), and cell
proliferation was analyzed using the Rapid cell proliferation kit (Calbiochem,
San Diego, CA) on days 1 and 3 posttransfection. In brief, 10 l of WST-1
reagent was added to each well and incubated at 37°C for 1 h, and absorbance
was read at 450 nm. All samples were performed in triplicate. Alternatively,
transfected cells (5  105) were plated in 60-mm dishes in triplicate, trypsinized,
and counted on days 2 to 3 posttransfection using a Z1 Coulter particle counter
(Beckman Coulter, Fullerton, CA).
Western blotting. Western blotting was performed essentially as described
previously (34). Proteins were detected and analyzed using the FUJI LAS-3000
system and Multi Gauge 3.0 software (Fuji, Japan).
Immunohistochemistry. Tissue blocks from five patients diagnosed with classic
papillary thyroid carcinoma were obtained from Yu Lv, Professor of Pathology,
Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing,
People’s Republic of China. Fresh hematoxylin and eosin sections were made
and reviewed by trained pathologists from the Hospital of the University of
Pennsylvania. Sections (5 m) were freshly cut for immunohistochemical stain-
ing. Sections were incubated at 58°C for 20 min, deparaffinized in xylene twice for
15 min, and rehydrated. Sections were incubated in antigen-unmasking solution
(Vector Laboratories, CA) at 95 to 98°C for 20 min and cooled to room tem-
perature, and endogenous peroxidase activity was blocked by incubation in 3%
H2O2 at room temperature for 15 min. Sections were washed in PBS-Tween,
incubated in blocking buffer (10% normal goat serum–1% bovine serum albumin
in PBS-Tween), and then incubated at 4°C overnight with primary antibody
(Rap1GAP, 1:500; Santa Cruz). Following washing, sections were stained with
biotinylated goat anti-rabbit IgG (1:200) for 30 min at room temperature,
washed, and incubated in ABC complex (Vector Vectastain Elite ABC kit) at
room temperature for 30 min. Bound antibody was visualized by DAB (Vector
Laboratories, CA). Sections were analyzed by two pathologists, and staining
intensity was scored as 1 to 5.
Graphic and statistical analyses. Statistical analyses were performed using
GraphPad Prism 3.0 software. Data are presented as means  standard devia-
tions, and significance was assessed by t test. A P value of 0.05 was considered
to be statistically significant.
RESULTS
Rap1GAP expression is abolished in human thyroid tumor
cell lines. We previously reported that Rap1GAP is abundant in
differentiated rat thyroid cells and suggested a role for Rap1GAP
as a tumor suppressor (34). Two recent reports provided support
for this hypothesis and showed that Rap1GAP expression was
decreased in oropharyngeal squamous cell (43) and pancreatic
(42) carcinomas. Here, we analyzed Rap1GAP expression in cell
lines isolated from human follicular, papillary, and anaplastic
thyroid carcinomas. Western blotting revealed that Rap1GAP
protein levels were markedly decreased in NPA, FTC-133, and
SW1736 cells compared to the other lines examined (Fig. 1A). As
NPA, FTC-133, and SW1736 cells were isolated from papillary,
follicular, and anaplastic carcinomas, respectively, the downregu-
lation of Rap1GAP was not correlated with a specific tumor
subtype. To assess whether the loss of the Rap1GAP protein
reflected transcriptional effects, Rap1GAP message levels were
examined. Rap1GAP mRNA was absent from FTC-133, NPA,
and SW1736 cells and present in ARO, KAT-4B, KAT-10, and
WRO cells (Fig. 1B), consistent with the notion that the rap1GAP
gene is silenced or lost during thyroid carcinogenesis.
We noted a striking correlation between the loss of ex-
pression of Rap1GAP and transformed morphology (Fig.
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1C). Tumor cell lines that expressed Rap1GAP (ARO,
KAT-4B, KAT-10, and WRO) exhibited an epithelial mor-
phology and formed well-defined colonies with extensive
cell-cell contacts, similar to WRT cells. In contrast, the
tumor cell lines that lacked Rap1GAP (FTC-133, NPA, and
SW1736) were fibroblast-like and exhibited extensive cell
scattering. Notably, the downregulation of Rap1GAP was
correlated with the loss of E-cadherin and the acquisition of
vimentin expression (Fig. 1A). Hence, these data revealed a
striking correlation between the loss of Rap1GAP and al-
terations in cell morphology and gene expression character-
istic of an epithelial-to-mesenchymal transition.
Rap1GAP inhibits cell spreading, migration, and invasion.
To assess if there were functional consequences associated with
Rap1GAP depletion, HA-Rap1GAP was expressed in FTC-133
cells using an adenovirus. Preliminary experiments were con-
ducted to determine the lowest dose of virus that resulted in
sufficient Rap1GAP expression to inhibit endogenous Rap1 ac-
tivity (Fig. 2A). Infection with the Rap1GAP virus dose-depen-
dently impaired Rap1 activity, with maximal inhibition observed
at an MOI of 4. Under these conditions, Rap1GAP-expressing
cells were impaired in their ability to adhere to and spread on
laminin-treated coverslips (Fig. 2B), consistent with the previ-
ously established roles of Rap in the regulation of cell adhesion
(reviewed in references 5 and 18). Rap1 has been shown to facil-
itate Rac activation by recruiting a subset of Rac guanine nucle-
otide exchange factors to the plasma membrane (3). Rac1 activity
in FTC-133 cells increased over time following replating, and this
was impaired by the expression of Rap1GAP (Fig. 2C and D).
The inhibition of Rac1 activity and cell spreading were transient
(data not shown), suggesting that Rap1GAP selectively inhibits
early events associated with cell attachment and spreading.
Expression of Rap1GAP in FTC-133 cells delayed wound
closure (Fig. 3A) and impaired actin polymerization at the
leading edge of migrating cells (Fig. 3B). To fortify these find-
ings, cell migration was analyzed in transwell assays. Compared
to LacZ virus-infected cells, the expression of Rap1GAP sig-
nificantly reduced cell migration (Fig. 3C) as well as epidermal
growth factor-induced invasion through a basement membrane
(Matrigel) (Fig. 3D). To assess whether Rap1GAP elicited
FIG. 1. Downregulation of Rap1GAP in human thyroid cancer cell lines. (A) Rap1GAP expression was analyzed by Western blotting in a panel
of human thyroid carcinoma cell lines (see Materials and Methods) and WRT cells. The same filter was probed for E-cadherin and vimentin. Equal
protein loading was confirmed by blotting for actin. More than three experiments were performed, with similar results. (B) Rap1GAP mRNA was
analyzed by RT-PCR. No DNA was added to the negative control (), and WRT cells provided a positive control. Four experiments were
performed, with similar results. (C) Phase-contrast images of human thyroid carcinoma and WRT cells.
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similar effects on other migratory thyroid tumor cell lines,
Rap1GAP was expressed in NPA cells. When expressed at
levels sufficient to block Rap1 activity (MOI of 8) (Fig. 3E),
Rap1GAP inhibited the migration of NPA cells (Fig. 3F).
To assess whether the inhibition of Rap activity was sufficient to
impair cell migration, dominant negative Rap1 (Rap1N17) was
expressed in FTC-133 cells using an adenovirus. The expression
of Rap1N17 inhibited cell migration in transwell (Fig. 4A) and
wound closure (data not shown) assays. As for Rap1GAP, the
dose response over which Rap1N17 inhibited Rap1 activity was
similar to that over which it impaired migration (data not shown).
We confirmed that the migration of FTC-133 cells required
Rac1 activity. The expression of 2-chimerin, a highly selective
RacGAP (38), inhibited both Rac1 activation (Fig. 4B) and cell
migration (Fig. 4C) with a similar dose response. Collectively,
these findings indicate that Rap1GAP impairs the migration of
human thyroid tumor cells, possibly through the inhibition of
Rac1 activity.
FIG. 2. Rap1GAP blocks Rac activation and cell spreading. (A) FTC-133 cells were infected with Rap1GAP or LacZ virus (at the MOIs indicated),
and Rap1 activity was assessed at 24 h postinfection. Two dose-response experiments were performed, with similar results. (B) Rap1GAP and LacZ
virus-infected (MOI of 4) FTC-133 cells were plated onto laminin-coated coverslips for the times indicated (minutes), fixed, and stained with rhodamine-
conjugated phalloidin. Two time course experiments were performed with similar results. More than 90% of Rap1GAP-infected cells were HA positive
(data not shown). (C and D) Rac1 activity was examined in Rap1GAP and LacZ (MOI of 4) virus-infected FTC-133 cells 4 h after plating. Total cell
extracts were analyzed for Rac1 and HA-Rap1GAP expression. Representative data and a summary from four experiments are presented. Rac1
activation in mock-infected cells () was set as 1. Rap1GAP significantly reduced Rac1 activity (, P  0.005).
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Rap1GAP inhibits cell proliferation. If Rap1GAP func-
tions as a tumor suppressor, manipulating its expression should
elicit effects on cell proliferation. We previously reported that
Rap1GAP inhibits cell proliferation when overexpressed in rat
thyroid cells (34). To assess whether decreased Rap1GAP expres-
sion contributed to the proliferation of human thyroid tumor
cells, the effects of restoring Rap1GAP expression on DNA syn-
thesis and anchorage-independent growth were investigated.
DNA synthesis was significantly reduced in Rap1GAP- versus
vector-transfected FTC-133 cells (Fig. 5A). Similarly, the tran-
FIG. 3. Rap1GAP inhibits the migration and invasion of human thyroid carcinoma cells. (A) Rap1GAP and LacZ virus-infected FTC-133 cells
(at the MOIs indicated) were plated to yield a confluent monolayer at 24 h postinfection. Cells were wounded, and images were acquired
immediately and 24 h later. Three experiments were performed, with similar results. (B) Immunostaining for HA-Rap1GAP and actin at 6 h after
wounding is shown. The extension of actin-rich cell protrusions was markedly impaired in Rap1GAP-expressing cells (arrow). Two experiments
were performed, with similar results. (C) At 24 h postinfection, FTC-133 cells were plated in transwell chambers, and cell migration was analyzed
(see Materials and Methods). Results from three independent experiments performed in triplicate are summarized. Rap1GAP significantly
inhibited cell migration (*, P  0.05). (D) Rap1GAP impaired the ability of FTC-133 cells to invade through Matrigel. Cells were infected as
described above (C) and plated in transwell chambers containing Matrigel-coated filters (see Materials and Methods). Results from two
independent experiments (triplicate samples) are shown. Rap1GAP significantly reduced invasion (*, P  0.05). (E) Rap1GAP dose-dependently
inhibited Rap1 activity in NPA cells. Two dose-response experiments performed at the MOIs indicated yielded similar results. (F) Rap1GAP and
LacZ virus-infected (MOI of 8) NPA cells were plated in transwell chambers, and cell migration was analyzed. Results from two experiments
(triplicate samples) are shown. Rap1GAP significantly decreased cell migration in NPA cells (*, P  0.05).
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sient expression of Rap1GAP reduced colony formation in agar
(Fig. 5B). To examine whether Rap1GAP negatively regulates
cell proliferation in differentiated rat thyroid cells, cell prolifera-
tion was analyzed in WRT cells in which Rap1GAP expression
was transiently reduced using RNA interference. The elimination
of Rap1GAP expression induced a significant increase in cell
proliferation, as assessed by increased mitochondrial activity (Fig.
5C) and cell number (Fig. 5D). Hence, the proliferation of dif-
ferentiated rat thyroid cells and human thyroid carcinoma cells is
sensitive to Rap1GAP expression levels.
Rap1GAP expression is downregulated by Ras transforma-
tion. To further assess the significance of Rap1GAP downregu-
lation to thyroid cell transformation, we examined whether the
downregulation of Rap1GAP could be induced by a thyroid
oncogene. Mutations in H-Ras, K-Ras, and N-Ras are frequent
in human thyroid tumors, where Ras contributes to tumor
initiation and progression (reviewed in references 25 and 36).
Strikingly, Rap1GAP protein (Fig. 6A) and message (data not
shown) levels were abolished in human H-Ras (RasV12)-trans-
formed thyroid cells (7, 26). The downregulation of Rap1GAP
was restricted to Ras proteins capable of signaling to the Raf/
MEK/ERK cascade, as Rap1GAP expression was abolished by
RasV12S35, a mutant that activates Raf (40), and retained in
cells transformed with RasV12G37 and RasV12C40, mutants
that signal preferentially to RalGDS and phosphatidylinositol
3-kinase, respectively. The downregulation of Rap1GAP was
correlated with increases in both Rap1 activity and expression
(Fig. 6B). Following normalization for differences in expres-
sion, Rap1 activity was increased in RasV12 and RasV12S35
cells compared to cells expressing the other Ras effector do-
main mutants (Fig. 6C).
The selective downregulation of Rap1GAP in RasV12- and
RasV12S35-expressing cells was striking in that only thyroid cells
transformed by these Ras proteins exhibited morphological trans-
formation (7, 26). Wound assays revealed that only RasV12- and
RasV12S35-expressing cells were migratory (Fig. 6D). As pre-
dicted, restoring Rap1GAP expression to RasV12S35 cells im-
paired wound closure (Fig. 6E) and transwell migration (Fig. 6F).
Similar effects were observed with Rap1N17 (data not shown).
Rap1GAP expression also blocked the invasion of RasV12S35
cells through Matrigel (data not shown).
Interference with Rap1 activity through the expression of ei-
ther Rap1GAP (Fig. 7A) or dominant negative Rap1 (Fig. 7B)
reduced Rac1 activity in RasV12S35 cells as in human thyroid
carcinoma cells (Fig. 2). Although the migration of RasV12S35
cells required MEK1 activity (Fig. 7C), the expression of
Rap1GAP in these cells or in FTC-133 cells did not decrease
ERK activity (Fig. 7D). Similar results were reported previously
for pancreatic carcinoma cell lines, where the stable expression of
Rap1GAP impaired cell motility and invasion but not ERK phos-
phorylation (42). Rac1 activity in RasV12S35 cells was insensitive
to the MEK1 inhibitor (data not shown). These data suggest that
multiple pathways contribute to the migration of RasV12S35
cells, only some of which are impaired by interference with Rap
activity. However, they do not exclude the inhibition of localized
pools of ERK by Rap1GAP, as Rap1 has been shown to selec-
FIG. 4. Rap1 and Rac1 activity are required for the migration of human thyroid carcinoma cells. (A) Rap1N17 and LacZ virus-infected
FTC-133 cells were plated in transwell chambers, and cell migration was analyzed. The remaining cells were analyzed for HA-Rap1N17 expression.
Results from three experiments are summarized. Rap1N17 significantly reduced cell migration (, P  0.005). (B) Infection with 2-chimerin but
not LacZ virus dose-dependently impaired Rac1 activity in FTC-133 cells. Results from three independent experiments are summarized. Rac1
activity in growing FTC-133 cells was set as 1. (C) 2-Chimerin dose-dependently impaired migration in FTC-133 cells. Cells were infected as
described above. Results from three independent experiments are summarized.
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tively activate plasma membrane-localized ERK (39). Thus, the
downregulation of Rap1GAP appears to contribute to the migra-
tory behavior of Ras-transformed rat thyroid cells as well as hu-
man thyroid tumor cell lines.
Acute expression of oncogenic Ras downregulates Rap1GAP
expression. To determine whether the downregulation of
Rap1GAP was an early event in Ras transformation, we analyzed
the acute effects of oncogenic Ras on Rap1GAP. WRT cells were
infected overnight with an adenovirus expressing activated H-Ras
(RasV12) (8), and Rap1GAP protein expression was analyzed
after 48 h. Rap1GAP expression was extinguished in a dose-
dependent manner following infection with human H-RasV12
but not LacZ-expressing adenovirus (Fig. 8A). Similar effects
were observed when Rap1GAP was analyzed after 24 h (data not
shown). The decrease in Rap1GAP required activated and mem-
brane-localized Ras, as the expression of cellular Ras (Ras G12)
or of an activated mutant impaired in membrane localization
(RasV12C186A) (8) did not affect Rap1GAP protein levels (data
not shown). Rap1GAP protein levels were partially restored by
treatment with the MEK1 inhibitor UO126 (Fig. 8B). In addition,
acute expression of RasV12S35 or constitutively active MEK1
was sufficient to decrease Rap1GAP protein levels (Fig. 8C). The
expression of RasV12 also decreased Rap1GAP message levels
(Fig. 8D). However, compared to LacZ virus-infected cells, treat-
ment with UO126 had little effect on Rap1GAP message levels in
RasV12-expressing cells. These results suggest that RasV12 elicits
potentially independent effects on Rap1GAP protein and mes-
sage levels. The acute downregulation of Rap1GAP by Ras re-
veals the potential for collaboration between Ras and Rap1 in
thyroid cell transformation.
Downregulation of Rap1GAP in primary thyroid tumors.
The loss of Rap1GAP from the thyroid tumor cell lines pro-
vided a compelling rationale for examining Rap1GAP expres-
sion in primary thyroid tumors. Five classic human papillary
FIG. 5. Rap1GAP regulates cell proliferation. (A) DNA synthesis was examined in Rap1GAP- versus vector (pShuttle)-transfected FTC-133
cells. Cells were pulse-labeled with BrdU for 4 h on day 1 posttransfection. Percent BrdU-positive versus total DAPI (4,6-diamidino-2-
phenylindole)-positive nuclei is shown for pShuttle, and percent BrdU-positive, HA-positive cells is shown for Rap1GAP. Results shown are
representative of three experiments (, P  0.05). (B) pShuttle HA-Rap1GAP and pShuttle-transfected FTC-133 cells were plated in soft agar at
day 1 posttransfection, and the number of colonies formed was assessed after 3 weeks. Data shown are representative of three independent
experiments (, P  0.001). (C) WRT cells were transfected with two different sets of Rap1GAP siRNAs (siGAP) (1 and 2) versus scrambled
controls (scr) and plated overnight, and cell proliferation was analyzed by WST-1 assay at days 1 (open bars) and 3 (black bars) posttransfection.
The optical density at 450 nm at day 1 was set as 1 for each sample. Parallel samples were analyzed for Rap1GAP expression. Results shown are
summarized from two experiments (, P 0.05). (D) WRT cells were transfected as described above (C) and plated overnight, and the cell number
was analyzed at days 2 (open bars) and 3 (black bars) posttransfection. The cell number at day 2 was set as 1 for each sample. Parallel samples
were analyzed for Rap1GAP expression. Results shown are summarized from three independent experiments (, P  0.05; , P  0.005).
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thyroid carcinomas were selected for analysis, as this is the
most frequent type of thyroid cancer. We restricted our anal-
ysis to tissue blocks that contained both normal tissue and
tumor tissue in the same sample. Rap1GAP expression was
examined by immunohistochemistry and scored independently
by two pathologists. As we predicted, Rap1GAP was highly
expressed in normal follicular epithelial cells (Fig. 9A and B).
Stromal cells, endothelial cells, and lymphocytes did not ex-
press Rap1GAP and served as internal negative controls for
Rap1GAP staining. Although Rap1GAP was detected in tu-
mor cells, there was a marked decrease in staining intensity in
these cells compared to normal thyroid tissue in the same
sample (Fig. 9A and C). Similar results were observed for all
five samples analyzed (Fig. 9D). These data strongly suggest
that Rap1GAP is downregulated in human thyroid tumors in
vivo.
DISCUSSION
One of the most critical steps in the progression to malig-
nancy is the acquisition of the ability to migrate and metasta-
size by tumor cells. As the most frequent endocrine malig-
nancy, and one whose incidence is increasing, thyroid cancer
poses a significant clinical challenge. There are no curative
therapies for patients with progressive or recurrent thyroid
cancer. An elucidation of the molecular events that contribute
to the metastatic progression of thyroid tumors is desperately
needed in order to devise more effective therapies.
FIG. 6. Rap1GAP is downregulated in Ras-transformed cells. (A) Rap1GAP expression was analyzed in WRT cells transformed with human
HA-RasV12 and the indicated Ras effector domain mutants (7, 26). Expression of HA-Ras is shown; Western blotting for actin confirmed equal
protein loading. (B and C) Rap1 activity was analyzed in parental and Ras-transformed cells. Normalization for Rap1 expression confirmed that
Rap1 activity was increased in RasV12 and RasV12S35 cells compared to the other lines. Rap1 activity in WRT cells was set as 1. Results shown
are summarized from two independent experiments. (D) Confluent RasV12-transformed cells were wounded, imaged immediately, and imaged
again after 24 h. Three experiments were performed, with similar results. (E) Rap1GAP and LacZ virus-infected (MOI of 6) RasV12S35 cells were
wounded and imaged immediately and after 48 h. Two experiments were performed, with similar results. (F) Rap1GAP and LacZ virus-infected
RasV12S35 cells were plated in transwell chambers, and cell migration was analyzed. Results from three experiments (triplicate samples) are
summarized.
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Rap1GAP is abundant in differentiated rat thyroid cells,
cells in which Rap1GAP protein stability is regulated by TSH
(34). As the expression of the TSH receptor is extinguished in
thyroid tumors, Rap1GAP expression was analyzed in human
follicular, papillary, and anaplastic thyroid tumor cell lines.
Rap1GAP expression was selectively abolished in lines that
were highly migratory. Decreased expression of Rap1GAP was
strictly correlated with the loss of E-cadherin and acquisition
of vimentin expression and mesenchymal morphology. Impor-
tantly, transient expression of Rap1GAP in the Rap1GAP-
deficient tumor cell lines inhibited cell migration and invasion.
Based on in vitro data, we hypothesized that Rap1GAP
expression would be decreased in invasive thyroid cancers
compared to normal thyroid tissue. To assess this, five classic
papillary thyroid cancers were analyzed for Rap1GAP protein
expression by immunohistochemistry. Rap1GAP staining was
decreased in all five tumors compared to adjacent normal
tissue. Although the tumor cells were not as mesenchymal in
morphology as the thyroid cancer cell lines, they were mor-
phologically dissimilar from normal thyroid follicular cells and
invasive clinically. Whether further reductions in Rap1GAP
expression would lead to more complete morphological trans-
formation remains to be determined. These results fortify our
in vitro data and implicate a role for Rap1GAP in thyroid
cancer. We are actively pursuing the significance of these find-
ings in a larger set of human thyroid cancers.
The mechanism through which Rap1GAP inhibits cell mo-
tility was explored in the FTC-133 follicular thyroid carcinoma
cell line (12). The results strongly suggest that Rap1GAP im-
pairs cell migration through the inhibition of Rap1 and Rac1
activity. However, while the expression of dominant negative
Rap1 inhibited cell migration, the depletion of Rap1A and
Rap1B expression failed to do so (data not shown). These
results suggest that low levels or specific pools of Rap1 or
additional targets of Rap1GAP, for example, Rap2 (24), con-
tribute to migratory behavior. Rap1GAP delayed the transient
increase in Rac1 activity induced by plating, consistent with
recent findings that Rap1 recruits Rac guanine nucleotide ex-
change factors to the plasma membrane (3). Similar to our
findings, the overexpression of Rap1GAP inhibited Rac1 ac-
tivity, membrane protrusion, and cell spreading in HeLa cells
(3); Rac1 activation by serotonin in COS cells expressing the
5-hydroxytryptamine receptor (23); and cell migration in hu-
man umbilical vein endothelial cells (9). Although Rac activity
was required for the migration of thyroid cancer cells, RacV12
failed to restore migration to Rap1GAP-expressing cells and
impaired migration when expressed alone (data not shown).
Thus, although it seems likely that Rap1GAP impairs migra-
tion through the inhibition of Rac1, sustained Rac1 activity is
not sufficient to restore cell migration. These results imply that
the cycling of Rac between GDP- and GTP-bound forms
FIG. 7. Interference with Rap1 activity impairs Rac1 but not ERK activity in Ras-transformed cells. (A) Rac1 activity was assessed in Rap1GAP
and LacZ virus-infected RasV12S35 cells. Rac1 activity in mock-infected cells () was set as 1. Results from three experiments are shown. (B) Rac1
activity was examined in Rap1N17 and LacZ virus-infected (MOI of 152) RasV12S35 cells. Rac1 activity in mock-infected cells was set as 1. Results
from two experiments performed in triplicate (, P  0.05) are summarized. (C) RasV12S35 cells were pretreated with 10 M UO126 (UO) for
30 min prior to wounding. Cells were imaged immediately and after 24 and 48 h. Three experiments were performed, with similar results.
(D) Activating phosphorylation of ERK2 was compared in LacZ versus Rap1GAP virus-infected RasV12S35 (MOI of 6) and FTC-133 (MOI of
4) cells at 24 h postinfection. Equal protein loading was confirmed by Western blotting for AKT1. Three experiments were performed with
RasV12S35 cells, and four were performed with FTC-133 cells, with similar results.
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and/or additional factors targeted by Rap1GAP contribute to
cell migration in these cells.
Rap1GAP expression has been found to be decreased in
other tumor types, suggesting that it may be a common event
in cell transformation. Rap1GAP expression was decreased in
invasive pancreatic carcinomas compared to benign lesions
(42) and in a mouse model of glioblastoma multiform (14).
Similar to the results reported here, the stable expression of
Rap1GAP in pancreatic carcinoma cell lines inhibited cell
motility (42). Our findings that the transient expression of
Rap1GAP is sufficient to inhibit migration argue that impaired
motility is a primary effect of Rap1GAP rather than a conse-
quence of secondary changes associated with the isolation of
stable cell lines. Rap1GAP decreased growth rate and tumor
formation when stably expressed in pancreatic carcinoma cells
(42) and slowed cell cycle progression in squamous cell carci-
nomas, although these effects were modest and seen only in
synchronized cells (43). We demonstrate that the transient
expression of Rap1GAP impairs tumor cell proliferation and,
importantly, that the elimination of Rap1GAP expression in-
duces a transient increase in cell proliferation. These findings
clearly indicate that Rap1GAP expression is a determinant of
proliferative capacity in some cells.
Activating mutations in H-ras, K-ras, and N-ras are prevalent in
follicular thyroid carcinomas (25, 36). Our findings identify
Rap1GAP as being a target for Ras and suggest that the depletion
of Rap1GAP contributes to at least some aspects of Ras trans-
formation. Rap1GAP protein and message levels were decreased
by transformation with RasV12 and RasV12S35 but not in re-
sponse to Ras mutants impaired in activating the Raf/MEK/ERK
cascade. Only RasV12 and RasV12S35 induced features of an
epithelial-to-mesenchymal transition in thyroid cells, including
the downregulation of E-cadherin and upregulation of vimentin
expression. As predicted, RasV12- and RasV12S35-transformed
thyroid cells were migratory, and the expression of Rap1GAP in
these cells inhibited cell migration and invasion.
The transient expression of RasV12 in rat thyroid cells
downregulated Rap1GAP at the protein and message levels.
Acute downregulation of Rap1GAP protein levels by Ras re-
quired MEK1 activity, and transient expression of activated
MEK1 was sufficient to decrease Rap1GAP protein expres-
sion. Acutely, RasV12 also decreased Rap1GAP message lev-
els; however, this decrease was largely insensitive to MEK1
inhibition, suggesting that Ras elicits multiple, independent
effects on Rap1GAP expression. Together with our previous
report that TSH regulates Rap1GAP protein stability, these
data indicate that Rap1GAP expression is subject to multiple
levels of regulation and raise the interesting question as to
whether Rap1GAP is a marker of thyroid differentiation that
can be extinguished by Ras. The mechanism through which
FIG. 8. RasV12 acutely downregulates Rap1GAP protein and message levels. (A) WRT cells were infected with RasV12 (300, 1,000, and 2,500
particles/cell) or LacZ (1,000 particles/cell) virus overnight, transferred into growth medium, and harvested after 48 h. Total cell lysates were
analyzed for endogenous Rap1GAP and HA-Ras expression. Western blotting for AKT1 confirmed equal protein loading. Three experiments were
performed, with similar results. (B) WRT cells were infected overnight with RasV12 or LacZ virus (300 particles/cell), transferred into growth
medium in the presence and absence of 10 M UO126, and harvested 48 h later. Rap1GAP expression and HA-Ras expression were analyzed.
Western blotting for AKT1 confirmed protein loading. Three experiments were performed, with similar results. (C) WRT cells were infected with
viruses expressing RasV12S35, activated MEK1 (C/A MEK), and -galactosidase (LacZ) (2,500 particles/cell), and Rap1GAP expression was
analyzed at 48 h. Expression of HA-Ras and MEK1 and ERK activity (ERK-p) are shown. Equal protein loading was confirmed by analyzing AKT1
expression. Three experiments were performed, with similar results. (D) WRT cells were infected with RasV12 and LacZ (1,000 particles/cell)
viruses overnight and then transferred into growth medium in the absence () and presence () of 10 M UO126 for 48 h. Cells were harvested,
total RNA was isolated, and Rap1GAP message levels were analyzed as described in the legend of Fig. 1B. Five experiments revealed that RasV12
decreased Rap1GAP mRNA. Two experiments revealed little or no effect of UO126 on Rap1GAP message levels.
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Ras decreases Rap1GAP message levels is under investigation.
Ras has been shown to upregulate the expression of DNA
methyltransferases in epithelial cells (31). Although a CpG-
rich island has been identified upstream from the rap1gap
transcriptional start site (42), the demethylating agent 5-aza-
cytidine failed to restore Rap1GAP expression in Ras-trans-
formed thyroid cells (our unpublished results). The acute ex-
pression of Ras induces chromosomal instability in rat thyroid
cells (1, 17). A loss of heterozygosity for rap1gap has been
reported for pancreatic carcinomas (42), tumors where Ras
mutations are frequent. Whether Ras induces losses or rear-
rangements that affect the chromosomal region containing
rap1gap (1p35-36) remains to be determined.
Although first identified as being a suppressor of Ras trans-
formation (16), it is now clear that Rap1 functions indepen-
dently from Ras in most instances. Recent genetic evidence
from Drosophila melanogaster revealed a collaboration be-
tween Ras and Rap1 in the regulation of ERK activity (27).
Other recent findings place Rap1 functionally downstream
from Ras. The Rap1 guanine nucleotide exchange factor
Epac2 contains cAMP and Ras association domains (reviewed
in reference 4). Elevations in cAMP induce a conformational
change in Epac2, resulting in the activation of Rap1 on endo-
membranes. When coexpressed with activated Ras, Epac2 lo-
calized to the plasma membrane, where it activated a pool of
membrane-localized Rap1 (20). Our data reveal a novel mech-
anism through which Ras might regulate Rap1 via the down-
regulation of Rap1GAP. The significance of this regulation
remains to be explored; however, the ability of Rap1GAP to
impair the migratory and invasive properties of Ras-trans-
formed cells raises the potential for collaborative effects of Ras
and Rap1 in the regulation of thyroid cell motility and perhaps
other aspects of cell transformation.
In sum, we provide evidence that Rap1GAP expression is
downregulated in primary thyroid tumors. This is particularly
noteworthy given the proposed roles for Rap in thyroid cell
proliferation (2) and transformation (32) together with the
regulation of Rap1GAP by TSH (34). Although widely used as
a tool to impair Rap activity, it is surprising how little is known
about the regulation and function of cellular Rap1GAP. Stud-
ies to assess whether Rap1GAP is a marker of a favorable
prognosis in thyroid cancer would reveal whether strategies to
express Rap1GAP in thyroid tumors should be exploited.
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